This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Non-Hodgkin lymphoma
  • /
  • Idelalisib: The First-in-Class Phosphatidylinosito...

Idelalisib: The First-in-Class Phosphatidylinositol 3-Kinase Inhibitor for Relapsed CLL, SLL, and Indolent NHL

Read time: 1 mins
Published:1st Nov 2014
Author: Forcello N, Saraiya N.
Availability: Free full text
Ref.:J Adv Pract Oncol. 2014 Nov-Dec; 5(6): 455-459.

Chronic lymphocytic leukemia (CLL) is a malignancy arising from a monoclonal population of mature B cells (Chiorazzi, Rai, & Ferrarini, 2005). Chronic lymphocytic leukemia is typically considered a disease of the elderly with a median age at diagnosis of approximately 70 years and is the most common adult leukemia in Westernized countries (Smolewski, Witkowska, & Korycka-Wolowiec, 2013). When these cells are predominantly found in the lymph nodes as compared to the bone marrow, the disease is referred to as small lymphocytic lymphoma (SLL; National Comprehensive Cancer Network [NCCN], 2014). As these disorders share some common characteristics with other B-cell neoplasms, they are frequently grouped in the classification known as indolent non-Hodgkin lymphoma (NHL).


Read abstract on library site

Access full article